WO1998052571A1 - Combinaisons antivirales contenant le nucleoside carbocyclique 1592u89 - Google Patents

Combinaisons antivirales contenant le nucleoside carbocyclique 1592u89 Download PDF

Info

Publication number
WO1998052571A1
WO1998052571A1 PCT/EP1998/002837 EP9802837W WO9852571A1 WO 1998052571 A1 WO1998052571 A1 WO 1998052571A1 EP 9802837 W EP9802837 W EP 9802837W WO 9852571 A1 WO9852571 A1 WO 9852571A1
Authority
WO
WIPO (PCT)
Prior art keywords
combination
amino
purin
cyclopropylamino
cyclopentene
Prior art date
Application number
PCT/EP1998/002837
Other languages
English (en)
Inventor
Martha Heider St. Clair
David Walter Barry
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9709945.1A external-priority patent/GB9709945D0/en
Priority claimed from GBGB9719866.7A external-priority patent/GB9719866D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Priority to JP54991298A priority Critical patent/JP2001525840A/ja
Priority to AU80172/98A priority patent/AU8017298A/en
Priority to EP98928261A priority patent/EP1019056A1/fr
Priority to CA002289654A priority patent/CA2289654A1/fr
Priority to NZ500868A priority patent/NZ500868A/en
Priority to BR9809124-7A priority patent/BR9809124A/pt
Publication of WO1998052571A1 publication Critical patent/WO1998052571A1/fr
Priority to NO995621A priority patent/NO995621L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Definitions

  • the present invention relates to therapeutic combinations of (-)-(l S, 4R) -4-[2-amino-6- (cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89) and HIV protease inhibitors, which have anti-HIV activity.
  • the present invention is also concerned with pharmaceutical compositions containing said combinations and their use in the treatment of HIV infections including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors.
  • the therapeutic agent 1592U89 (European Specification EP0434450) is a promising anti- HIV chemotherapeutic candidate (International Conference on Antiviral Research, April 23, 1995) showing potent activity against Human Immunodeficiency Virus (HIV), the causative agent of Acquired Immune Deficiency Syndrome (AIDS), low cytotoxicity and excellent penetration into the brain which is important for the treatment of AIDS and
  • HIV linked central nervous system conditions such as AIDS dementia complex.
  • HIV protease inhibitor compounds have potent activity against HIV and related conditions such as AIDS-related Complex (ARC).
  • HIV protease inhibitor compounds include those disclosed in WO 94/05639, WO 95/24385, WO 94/13629, WO 92/16501 , WO
  • nucleoside reverse transcriptase inhibitors such as zidovudine, didanosine (ddl), zaicitabine (ddC) and stavudine (d4T).
  • zidovudine didanosine
  • ddC didanosine
  • ddC zaicitabine
  • d4T stavudine
  • a combination comprising 1592U89 or a physiologically functional derivative thereof, and at least one HIV protease inhibitor or a physiologically functional derivative thereof.
  • a further feature of the present invention is a combination comprising 1592U89, at least one HIV protease inhibitor, and a second reverse transcriptase inhibitor, such as lamivudine.
  • the ratios of the components of such combinations will conveniently be the same as the ratios of the relevant compounds in the double combinations of the invention.
  • physiologically functional derivative includes any physiologically acceptable solvate, salt, ether, ester, salt of such ester, or solvates of any such salt, ether, or ester, of 1592U89 or HIV protease inhibitor(s); or any other compound which upon administration to the recipient, is capable of providing (directly or indirectly) such a compound or an antivirally active metabolite or residue thereof.
  • Preferred esters in accordance with the invention are independently selected from the following group: (1) carboxylic acid esters in which the non-carbonyl moiety of the carboxylic acid portion of the ester grouping is selected from straight or branched chain alkyl (for example, methyl, jn-propyl, t-butyl, or n-butyl), cycloalkyi, alkoxyalkyl (for example, methoxymethyl), aralkyl (for example, benzyl), aryloxyalkyl (for example, phenoxymethyl), aryl (for example, phenyl optionally substituted by, for example, halogen, C-_ 4 alkyl, or C,_ 4 alkoxy), or amino; (2) sulphonate esters, such as alkyl- or aralkylsulphonyl (for example, methanesulphonyl); (3) amino acid esters (for example, L- valyl or L-isoleucyl); and (4) phospho
  • any alkyl moiety present advantageously contains from 1 to 18 carbon atoms, particularly from 1 to 6 carbon atoms, more particularly from 1 to 4 carbon atoms.
  • Any cycloalkyi moiety present in such esters advantageously contains from 3 to 6 carbon atoms.
  • Any aryl moiety present in such esters advantageously comprises a phenyl group. Any reference to any of the above compounds also includes a reference to a physiologically acceptable salt thereof.
  • Preferred derivatives of 1592U89 are the mono-, di-, and tri-phosphate esters of (1 R, 4S)-9-[4-(hydroxymethyl)-2-cyclopenten-1 -yl]guanine (carbovir).
  • physiologically acceptable salts of 1592U89 or HIV protease inhibitor(s) and their physiologically acceptable derivatives include salts derived from an appropriate base, such as an alkali metal (for example, sodium), an alkaline earth (for example, magnesium), ammonium and NX 4 (wherein X is C-_ 4 alkyl).
  • an appropriate base such as an alkali metal (for example, sodium), an alkaline earth (for example, magnesium), ammonium and NX 4 (wherein X is C-_ 4 alkyl).
  • Physiologically acceptable salts of an hydrogen atom or an amino group include salts of organic carboxylic acids such as acetic, lactic, tartaric, malic, isethionic, lactobionic, and succinic acids, organic sulphonic acids, such as methanesulphonic, ethanesulphonic, benzenesuiphonic and p- toluenesulphonic acids and inorganic acids, such as hydrochloric, sulphuric, phosphoric and sulphamic acids.
  • Physiologically acceptable salts of a compound of an hydroxy group include the anion of said compound in combination with a suitable cation such as Na + , NH 4 + and NX 4 (wherein X is a C,_ 4 alkyl group).
  • salts of 1592U89 or HIV protease inhibitor(s) will be physiologically acceptable, i.e. they will be salts derived from a physiologically acceptable acid or base.
  • salts of acids or bases which are not physiologically acceptable may also find use, for example, in the preparation or purification of a physiologically acceptable compound. All salts, whether or not derived from a physiologically acceptable acid or base, are within the scope of the present invention.
  • Preferred salts of 1592U89 are the succinate salt and the hemisulphate salt.
  • Combinations of 1592U89 or a physiologically functional derivative thereof and HIV protease inhibitor(s) or a physiologically functional derivative thereof may hereinafter be referred to as combinations according to the invention.
  • the present invention further provides combinations according to the invention for use in the treatment of an HIV infection including infections with HIV mutants bearing resistance to nucleoside inhibitors, particularly zidovudine, lamivudine, ddl, ddC or d4T or combinations thereof and non-nucleoside inhibitors such as nevirapine (BI-RG-587), loviride (a-APA) and delavridine (BHAP).
  • nucleoside inhibitors particularly zidovudine, lamivudine, ddl, ddC or d4T or combinations thereof and non-nucleoside inhibitors
  • nevirapine BI-RG-587
  • loviride a-APA
  • delavridine BHAP
  • the combinations according to the invention are especially useful for the treatment of AIDS and related clinical conditions such as AIDS related complex (ARC), progressive generalized lymphadenopathy (PGL), Kaposi's sarcoma, thrombocytopenic purpura, AIDS-related neurological conditions such as AIDS dementia complex, multiple sclerosis or tropical paraperesis, and also anti-HIV antibody-positive and HIV-positive conditions, including such conditions in asymptomatic patients.
  • AIDS related complex ARC
  • PDL progressive generalized lymphadenopathy
  • Kaposi's sarcoma Kaposi's sarcoma
  • thrombocytopenic purpura AIDS-related neurological conditions
  • AIDS dementia complex dementia complex
  • multiple sclerosis or tropical paraperesis and also anti-HIV antibody-positive and HIV-positive conditions, including such conditions in asymptomatic patients.
  • the present invention provides a method for the treatment of an HIV infection in an infected animal, for example, a mammal including a human, which comprises treating said animal with a therapeutically effective amount of a combination of 1592U89, or a physiologically functional derivative thereof, and one or more HIV protease inhibitors or a physiologically functional derivative thereof.
  • Reference herein to treatment extends to prophylaxis as well as the treatment of established infections or symptoms.
  • the compounds of the combination may be administered simultaneously, either in the same or different pharmaceutical formulations or sequentially. If there is sequential administration, the delay in administering the second and any subsequent active ingredient should not be such as to lose the benefit of a synergistic therapeutic effect of the combination of the active ingredients. It will also be understood that the compounds of the combination or the physiologically functional derivatives of any thereof, whether presented simultaneously or sequentially, may be administered individually or in multiples or in any combination thereof. 1592U89 and HIV protease inhibitor(s) are preferably administered simultaneously or sequentially in separate pharmaceutical formulations, most preferably simultaneously.
  • the present invention also provides the use of 1592U89 in the manufacture of a medicament for administration simultaneously or sequentially with one or more HIV protease inhibitors for the treatment and/or prophylaxis of HIV infections and associated clinical conditions hereinbefore described. It will be appreciated that 1592U89 and one or more HIV protease inhibitors may be used in the manufacture of the above medicament.
  • the synergistic effects of the combination of 1592U89 and an HIV protease inhibitor or a physiologically functional derivative of any thereof are seen over a ratio, for example, of 1 to 10: 1 to 20 (by weight), preferably 1 to 5: 1 to 10 (by weight), particularly 1 to 2: 1 to 3 (by weight).
  • Convenient ratios of 1592U89 to an HIV protease inhibitor include 1 :1.5, 1 :2, 1 :3, and 1 :4.
  • each compound may be employed in the combination in an amount at which it exhibits antiviral activity when used alone.
  • the amount of a combination of 1592U89 and one or more protease inhibitors required to be effective as an anti-HIV agent may, of course, vary and is ultimately at the discretion of the medical practitioner.
  • the factors to be considered include the route of administration and nature of the formulation, the animal's body weight, age and general condition and the nature and severity of the disease to be treated.
  • a suitable dose of an HIV protease inhibitor for administration to a human may be in the range of 5 to 100 mg per kilogram body weight per day, advantageously in the range of 8 to 70 mg per kilogram body weight per day, and preferably in the range of 8 to 50 mg per kilogram body weight per day.
  • a suitable dose of 1592U89 for administration to a human for treatment of an HIV injection may be in the range of 0.1 to 120 mg per kilogram body weight of the recipient per day, advantageously in the range of 3 to 90 mg per kilogram body weight per day and preferably in the range 5 to 60 mg per kilogram body weight per day.
  • the desired dose may preferably be presented as one, two, three, four, five, six or more sub-doses administered at appropriate intervals throughout the day.
  • sub-doses may be administered in unit dosage forms, for example, containing from 1 to 1500 mg, preferably from 5 to 1000 mg, most preferably from 10 to 700 mg of active ingredient per unit dosage form.
  • the dose may be administered as a continuous infusion.
  • the components of the combination which may be referred to as active ingredients may be administered for therapy to an animal e.g. a mammal including a human in a conventional manner.
  • compositions according to the present invention comprise a combination according to the invention together with one or more pharmaceutically acceptable carriers or excipients and optionally other therapeutic agents.
  • the carrier(s) must be acceptable in the sense of being compatible with the other ingredients of the formula and not deleterious to the recipient thereof.
  • the individual components of the combination are administered separately they are generally each presented as a pharmaceutical formulation.
  • the references hereinafter to formulations refer unless otherwise stated to formulations containing either the combination or a component thereof.
  • a combination of 1592U89 and one or more HIV protease inhibitors, or a physiologically functional derivative of any thereof may conveniently be presented as a pharmaceutical formulation in a unitary dosage form.
  • a convenient unitary dosage formulation contains the active ingredients in amounts of from 50 mg to 3 g each, for example, 100 mg to 2 g.
  • a typical unitary dosage may contain 50 mg to 3 g each of 1592U89 and one or more HIV protease inhibitors, advantageously 100 mg to 2 g each of 1592U89 and one or more HIV protease inhibitors.
  • a further feature of the present invention is a unitary dosage form comprising at least two active ingredients selected from 1592U89 and one or more HIV protease inhibitors or physiologically functional derivatives of any thereof and a pharmaceutically acceptable carrier therefor.
  • compositions are often prescribed to the patient in "patient packs" containing the whole course of treatment in a single package, usually a blister pack.
  • Patient packs have an advantage over traditional prescriptions, where a pharmacist divides a patient's supply of a pharmaceutical from a bulk supply, in that the patient always has access to the package insert contained in the patient pack, normally missing in traditional prescriptions.
  • the inclusion of a package insert has been shown to improve patient compliance with the physician's instructions and, therefore, lead generally to more successful treatment.
  • a multiple, for example, double or triple, pack comprising at least one active ingredient 1592U89 and one or more HIV protease inhibitors of the combination of the invention and an information insert containing directions on the use of the combination of the invention.
  • the invention provides a patient pack comprising in association for separate administration 1592U89 or a physiologically functional derivative thereof together with at least one HIV protease inhibitor or a physiologically functional derivative thereof.
  • Formulations include those suitable for oral, rectal, nasal, topical (including transdermal, buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration.
  • the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. Such methods represent a further feature of the present invention and include the step of bringing into association the active ingredients with the carrier which constitutes one or more accessory ingredients.
  • the formulations are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then if necessary shaping the product.
  • Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, caplets, cachets or tablets each containing a predetermined amount of the active ingredients; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
  • the active ingredient may also be presented as a bolus, electuary or paste.
  • a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine the active ingredients in a free-flowing form such as a powder or granules, optionally mixed with a binder (e.g. povidone, gelatin, hydroxypropyl methyl cellulose), lubricant, inert diluent, preservative, disintegrant (e.g. sodium starch glycollate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose) surface-active or dispersing agent.
  • Molded tablets may be made by molding a mixture of the powdered compound moistened with an inert liquid diluent in a suitable machine.
  • the tablets may optionally be coated or scored any may be formulated so as to provide slow or controlled release of the active ingredients therein using, for example, hydroxypropyl methyl cellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach.
  • Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredients in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • Formulations for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.
  • Topical administration may also be by means of a transdermal iontophoretic device.
  • Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • compositions suitable for rectal administration wherein the carrier is a solid are most preferably presented as unit dose suppositories.
  • Suitable carriers include cocoa butter and other materials commonly used in the art.
  • the suppositories may be conveniently formed by admixture of the active combination with the softened or melted carrier(s) followed by chilling and shaping in molds.
  • Formulations suitable for parenteral administration include aqueous and nonaqueous isotonic sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents; and liposomes or other microparticulate systems which are designed to target the compound to blood components or one or more organs.
  • the formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injection, immediately prior to use.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
  • Preferred unit dosage formulations are those containing a daily dose or daily subdose of the active ingredients, as hereinbefore recited, or an appropriate fraction thereof.
  • formulations of this invention may include other agents conventional in the art having regard to the type of formulation in question, for example, those suitable for oral administration may include such further agents as sweeteners, thickeners and flavoring agents.
  • the compounds of the combination of the present invention may be obtained in a conventional manner.
  • 1592U89 may be prepared by the method described in European Specification EP0434450, PCT application PCT/GB/4500225, PCT/GB95/02014, U.S. Patent No. 5,034,394, or GB9709945.1 which are incorporated herein by reference.
  • HIV protease inhibitors may be prepared by any method known to persons skilled in the art, for examples those methods disclosed in WO 94/05639, WO 95/24385, WO 94/13629, WO 92/16501 , WO 95/16688, W0/US94/13085, W0/US94/12562, US 93/59038, EP 541 168, WO 94/14436, WO 95/09843, WO 95/32185, WO 94/15906, WO 94/15608, WO
  • HIV RNA PCR (log-ocopies/ml) 4.54 (9) 2.60 (9) 2.60 (8) 2.60 (8) 2.60 (8)
  • HIV DNA PCR copies/10 5 cells
  • 132 not tested not tested not tested 15
  • CD4+ cells x 10 5 /L 315 (9) 314 (9) 314 (9) 517 (7) 489 (8)
  • formulations A, B and C are prepared by wet granulation of the ingredients with a solution of povidone, followed by addition of magnesium stearate and compression.
  • formulations D and E are prepared by direct compression of the admixed ingredients.
  • the lactose in formulation E is of the direct compression type (Dairy Crest- "Zeparox").
  • the formulation is prepared by wet granulation of the ingredients with a solution of povidone followed by the addition of magnesium stearate and compression.
  • Drug release takes place over a period of about 6-8 hours and is complete after 12 hours.
  • a capsule formulation is prepared by admixing the ingredients of formulation D in Example 2 above and filling into a two-part hard gelatin capsule.
  • Formulation B (infra) is prepared in a similar manner.
  • Capsules of formulation C are prepared by melting the Macrogel 4000 B.P., dispersing the active ingredient in the melt and filling the melt into a two-part hard gelatin capsule.
  • Capsules of formulation D are prepared by dispersing the active ingredient in the lecithin and arachis oil and filling the dispersion into soft, elastic gelatin capsules.
  • Vitamin E TPGS obtained from Eastman Chemical Co.
  • PEG400 polyethylene glycol 400
  • the following controlled release capsule formulation is prepared by extruding ingredients a,b, and c using an extruder, followed by spheronization of the extrudate and drying. The dried pellets are then coated with release-controlling membrane (d) and filled into a two-piece, hard gelatin capsule.
  • Active Ingredient 200 Hydro chloric Acid Solution 0.1 M or
  • the active ingredient is dissolved in most of the water (35 - 40 C) and the pH adjusted to between 4.0 and 7.0 with the hydrochloric acid or the sodium hydroxide as appropriate.
  • the batch is then made up to volume with water and filtered through a sterile micropore filter into a sterile 10 ml amber glass vial (type 1 ) and sealed with sterile closures and overseals.
  • the active ingredient is dissolved in the glycofurol.
  • the benzyl alcohol is then added and dissolved, and water added to 3 ml.
  • the mixture is then filtered through a sterile micropore filter and sealed in sterile 3 ml amber glass vials (type 1).
  • the active ingredient is dissolved in a mixture of the glycerol and most of the purified water.
  • An aqueous solution of the sodium benzoate is then added to the solution, followed by addition of the sorbital solution and finally the flavor.
  • the volume is made up with purified water and mixed well.
  • Example 7 Suppository mg/capsule suppository
  • Witepsol Hi 5 One-fifth of the Witepsol Hi 5 is melted in a steam-jacketed pan at 45°C maximum.
  • the active ingredient is sifted through a 200 ⁇ m sieve and added to the molten base with mixing, using a Silverson fitted with a cutting head, until a smooth dispersion is achieved. Maintaining the mixture at 45 C, the remaining Witepsol Hi 5 is added to the suspension and stirred to ensure a homogenous mix.
  • the entire suspension is passed through a 250 ⁇ m stainless steel screen and, with continuous stirring, is allowed to cool to 45° C. At a temperature of 38° C to 40° C, 2.02 g of the mixture is filled into suitable, 2 ml plastic molds. The suppositories are allowed to cool to room temperature.
  • Active Ingredient 250 Anhydrate Dextrose 380

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne des combinaisons thérapeutiques de (-)-(1S, 4R)-4-[2-amino-6- (cyclopropylamino)-9H-purin-9-yl] -2-cyclopentène-1-méthanol (1592U89) et des inhibiteurs de la protéase du VIH présentant une activité anti-VIH. L'invention concerne également des compositions pharmaceutiques contenant lesdites combinaisons et leur utilisation dans le traitement des infections par le VIH.
PCT/EP1998/002837 1997-05-17 1998-05-14 Combinaisons antivirales contenant le nucleoside carbocyclique 1592u89 WO1998052571A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP54991298A JP2001525840A (ja) 1997-05-17 1998-05-14 炭素環式ヌクレオシド１５９２ｕ８９を含有する抗ウイルス的組合せ
AU80172/98A AU8017298A (en) 1997-05-17 1998-05-14 Antiviral combinations containing the carbocyclic nucleoside 1592u89
EP98928261A EP1019056A1 (fr) 1997-05-17 1998-05-14 Combinaisons antivirales contenant le nucleoside carbocyclique 1592u89
CA002289654A CA2289654A1 (fr) 1997-05-17 1998-05-14 Combinaisons antivirales contenant le nucleoside carbocyclique 1592u89
NZ500868A NZ500868A (en) 1997-05-17 1998-05-14 Antiviral combinations comprising 1592U89 and HIV protease inhibitors
BR9809124-7A BR9809124A (pt) 1997-05-17 1998-05-14 Combinação, formulação, farmacêutica, processo para o tratamento de uma infecção por hiv em um animal, infectado, uso de (-)-(1s, 4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-cicl openteno-1-metanol, e, pacote de paciente
NO995621A NO995621L (no) 1997-05-17 1999-11-16 Antivirale kombinasjoner inneholdende karbocyklisk nukleoid 1592U89

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9709945.1A GB9709945D0 (en) 1997-05-17 1997-05-17 A novel salt
GB9709945.1 1997-05-17
GB9719866.7 1997-09-19
GBGB9719866.7A GB9719866D0 (en) 1997-09-19 1997-09-19 Antiviral Combinations

Publications (1)

Publication Number Publication Date
WO1998052571A1 true WO1998052571A1 (fr) 1998-11-26

Family

ID=26311542

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/002837 WO1998052571A1 (fr) 1997-05-17 1998-05-14 Combinaisons antivirales contenant le nucleoside carbocyclique 1592u89

Country Status (8)

Country Link
EP (1) EP1019056A1 (fr)
JP (1) JP2001525840A (fr)
AU (1) AU8017298A (fr)
BR (1) BR9809124A (fr)
CA (1) CA2289654A1 (fr)
NO (1) NO995621L (fr)
NZ (1) NZ500868A (fr)
WO (1) WO1998052571A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999063998A1 (fr) * 1998-06-11 1999-12-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouvelle utilisation de composes inhibiteurs de la protease du vih
WO2003030886A2 (fr) * 2001-10-05 2003-04-17 Elan Pharmaceuticals, Inc Allylamides utilises dans le traitement de la maladie d'alzheimer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006844A1 (fr) * 1994-08-26 1996-03-07 The Wellcome Foundation Limited Utilisation du succinate de 4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-2-cyclopentene-methanol comme agent antiviral
WO1996033184A1 (fr) * 1995-04-19 1996-10-24 Vertex Pharmaceuticals Incorporated Sulfamides contenant tetrahydrofurane (thf) et agissant comme inhibiteurs de la protease aspartyle
WO1996033187A1 (fr) * 1995-04-19 1996-10-24 Vertex Pharmaceuticals Incorporated Sulfamides contenant des heterocycles oxygenes et agissant comme inhibiteurs de l'aspartyle protease
WO1997020554A1 (fr) * 1995-12-05 1997-06-12 Vertex Pharmaceuticals Incorporated Traitement des effets du vih sur le systeme nerveux central avec le vx478, seul ou en combinaison avec l'azt ou le 3tc
WO1997027180A1 (fr) * 1996-01-26 1997-07-31 Vertex Pharmaceuticals Incorporated Inhibiteurs de l'aspartyle protease
WO1997049410A1 (fr) * 1996-06-25 1997-12-31 Glaxo Group Limited Combinaisons a base de vx478, zidovudine et/ou 1592u89 prevues pour etre utilisees dans le traitement du vih

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006844A1 (fr) * 1994-08-26 1996-03-07 The Wellcome Foundation Limited Utilisation du succinate de 4-(2-amino-6-(cyclopropylamino)-9h-purin-9-yl)-2-cyclopentene-methanol comme agent antiviral
WO1996033184A1 (fr) * 1995-04-19 1996-10-24 Vertex Pharmaceuticals Incorporated Sulfamides contenant tetrahydrofurane (thf) et agissant comme inhibiteurs de la protease aspartyle
WO1996033187A1 (fr) * 1995-04-19 1996-10-24 Vertex Pharmaceuticals Incorporated Sulfamides contenant des heterocycles oxygenes et agissant comme inhibiteurs de l'aspartyle protease
WO1997020554A1 (fr) * 1995-12-05 1997-06-12 Vertex Pharmaceuticals Incorporated Traitement des effets du vih sur le systeme nerveux central avec le vx478, seul ou en combinaison avec l'azt ou le 3tc
WO1997027180A1 (fr) * 1996-01-26 1997-07-31 Vertex Pharmaceuticals Incorporated Inhibiteurs de l'aspartyle protease
WO1997049410A1 (fr) * 1996-06-25 1997-12-31 Glaxo Group Limited Combinaisons a base de vx478, zidovudine et/ou 1592u89 prevues pour etre utilisees dans le traitement du vih

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ST CLAIR M H ET AL: "IN VITRO ANTIVIRAL ACTIVITY OF 141W94 (VX-478) IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS", ANTIVIRAL RESEARCH, vol. 29, no. 1, 1996, pages 53 - 56, XP000652574 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999063998A1 (fr) * 1998-06-11 1999-12-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouvelle utilisation de composes inhibiteurs de la protease du vih
FR2779653A1 (fr) * 1998-06-11 1999-12-17 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
US6506555B1 (en) 1998-06-11 2003-01-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of HIV protease inhibiting compounds
EP1637139A2 (fr) * 1998-06-11 2006-03-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouvelle utilisation de composés inhibiteurs de la protéase du VIH
EP1637139A3 (fr) * 1998-06-11 2006-08-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouvelle utilisation de composés inhibiteurs de la protéase du VIH
WO2003030886A2 (fr) * 2001-10-05 2003-04-17 Elan Pharmaceuticals, Inc Allylamides utilises dans le traitement de la maladie d'alzheimer
WO2003030886A3 (fr) * 2001-10-05 2003-08-07 Elan Pharm Inc Allylamides utilises dans le traitement de la maladie d'alzheimer

Also Published As

Publication number Publication date
BR9809124A (pt) 2000-08-01
NZ500868A (en) 2001-08-31
NO995621L (no) 2000-01-14
NO995621D0 (no) 1999-11-16
EP1019056A1 (fr) 2000-07-19
AU8017298A (en) 1998-12-11
CA2289654A1 (fr) 1998-11-26
JP2001525840A (ja) 2001-12-11

Similar Documents

Publication Publication Date Title
US6417191B1 (en) Synergistic combinations of zidovudine, 1592U89 and 3TC
EP0938321B1 (fr) Combinaisons comprenant du vx478, de la zidovudine et du 3tc pouvant etre utilisees dans le traitement du vih
AU723877C (en) Combinations comprising VX478, zidovudine and/or 1592U89 for use in the treatment of HIV
EP0979082A1 (fr) Combinaisons antivirales contenant le nucleoside carbocyclique 1592u89
US6432966B2 (en) Antiviral combinations
WO1998052571A1 (fr) Combinaisons antivirales contenant le nucleoside carbocyclique 1592u89
EP1113803A1 (fr) Combinaisons antivirales contenant de la lamivudine et de l'abacavir
WO2000018384A2 (fr) Combinaisons antivirales renfermant un ester isopropylique d'acide (s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydro-2h-quinoxaline-1-carboxylique
MXPA98010386A (en) Combinations that include vx478, zidovudina and / or 1592u89 for use in the treatment of
WO2000016754A2 (fr) Combinaisons antivirales
WO2000018383A2 (fr) Combinaisons antivirales renfermant un ester isopropylique d'acide (s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydro-2h-quinoxaline-1-carboxylique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 80172/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 500868

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 09423530

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2289654

Country of ref document: CA

Ref country code: CA

Ref document number: 2289654

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998928261

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 549912

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998928261

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1998928261

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998928261

Country of ref document: EP